Vaniqa

How to order Vaniqa

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Vaniqa on Prescriptsy

Vaniqa is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Vaniqa is a topical prescription cream containing eflornithine hydrochloride 11.5% (equivalent to 13.9% eflornithine hydrochloride monohydrate), licensed in the United Kingdom for the treatment of facial hirsutism in women.

Facial hirsutism refers to the growth of coarse, dark, terminal hair in areas of the face where women do not typically have visible hair, including the upper lip, chin, cheeks, and jawline.

Vaniqa is the only topical prescription treatment specifically developed to slow the rate of unwanted facial hair growth, and it is used alongside existing hair removal methods rather than as a replacement for them.

Facial hirsutism affects an estimated 5 to 15% of women in the UK, depending on ethnicity and the diagnostic criteria used.

It is a common presenting complaint in primary care and gynaecology clinics and can have a profound impact on psychological wellbeing, self-esteem, social functioning, and quality of life.

While facial hirsutism is frequently associated with polycystic ovary syndrome (PCOS), it can also occur as an idiopathic condition with no identifiable hormonal abnormality.

This page provides a detailed clinical overview of Vaniqa, including how it works, application instructions, clinical evidence, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Vaniqa

Before reading further, note the following key safety points about Vaniqa.

• Vaniqa slows facial hair growth but does not remove existing hair. Continue your usual hair removal method alongside treatment.
• Apply only to the face and adjacent chin. Do not use on other parts of the body.
• Wait at least 5 minutes after hair removal before applying Vaniqa, and at least 5 minutes after applying Vaniqa before applying sunscreen or cosmetics.
• If no improvement is seen after 4 months of consistent use, discontinue treatment and consult your prescriber.

What is facial hirsutism

Hirsutism is defined as the growth of terminal (coarse, pigmented) hair in women in a male-pattern distribution, including the upper lip, chin, chest, abdomen, and thighs.

The severity is often assessed using the modified Ferriman-Gallwey scoring system, which evaluates hair growth across nine body sites.

A score of 8 or above is generally considered diagnostic of hirsutism, although thresholds may vary by ethnicity.

Facial hirsutism specifically refers to unwanted terminal hair growth on the face, which is the most visible and socially distressing component of the condition.

The most common cause of hirsutism in women is polycystic ovary syndrome (PCOS), which accounts for approximately 70 to 80% of cases.

PCOS is characterised by hyperandrogenism (elevated levels of male hormones such as testosterone), oligo-anovulation (irregular or absent periods), and polycystic ovarian morphology on ultrasound.

Other causes include idiopathic hirsutism (where androgen levels are normal but the hair follicles are more sensitive to circulating androgens), non-classic congenital adrenal hyperplasia, Cushing syndrome, androgen-secreting tumours of the ovaries or adrenal glands, and medication-related hirsutism.

A thorough clinical and biochemical evaluation is recommended before starting treatment to exclude treatable underlying causes.

How Vaniqa works: mechanism of action

Eflornithine, the active ingredient in Vaniqa, is an irreversible inhibitor of ornithine decarboxylase (ODC).

ODC is a rate-limiting enzyme in the biosynthesis of polyamines, which are small polycationic molecules (putrescine, spermidine, and spermine) essential for cell proliferation and differentiation.

In the hair follicle, ODC activity is particularly high in the matrix cells of actively growing (anagen phase) follicles.

By irreversibly binding to and inactivating ODC, eflornithine depletes intracellular polyamine pools, thereby reducing the rate of cell division within the follicle matrix and slowing hair shaft elongation.

The effect of eflornithine is cytostatic rather than cytotoxic. It slows hair growth without destroying the hair follicle or altering its structure permanently.

When treatment is stopped, ODC activity recovers as new enzyme molecules are synthesised, and hair growth returns to its pre-treatment rate within approximately 8 weeks.

This is why Vaniqa must be used continuously to maintain its benefit, and why it is designed to be used alongside physical hair removal methods that address existing hair.

Percutaneous absorption of eflornithine from the 11.5% cream formulation is very low, with less than 1% of the applied dose reaching systemic circulation under normal conditions of use.

The absorbed fraction is not metabolised in the skin and is eliminated renally with a plasma half-life of approximately 8 hours.

This minimal systemic exposure contributes to the drug's favourable safety profile when used topically.

Clinical evidence for Vaniqa

The efficacy and safety of Vaniqa were established in two pivotal randomised, double-blind, vehicle-controlled clinical trials involving over 590 women with moderate to severe facial hirsutism.

After 24 weeks of twice-daily application, approximately 58% of women treated with eflornithine cream showed clinically meaningful improvement in facial hirsutism compared with 34% in the vehicle control group, as assessed by both physicians and patients.

Improvement was seen as early as 8 weeks, with continued benefit over the 24-week treatment period.

A further study examined the combination of eflornithine cream with laser hair removal and found that the combination produced significantly greater reduction in facial hair than either treatment alone.

This supports the use of Vaniqa as an adjunct to physical hair removal modalities.

Post-marketing surveillance and real-world prescribing data have confirmed the tolerability profile observed in clinical trials, with local skin reactions being the most commonly reported adverse effects.

How to apply Vaniqa

Correct application technique is important for achieving optimal results with Vaniqa.

• Clean and dry the affected areas of the face before application.
• Apply a thin layer of cream to the areas of unwanted facial hair growth, including the upper lip, chin, cheeks, and jawline as applicable. Rub the cream in thoroughly until it is no longer visible on the skin.
• Apply twice daily, at least 8 hours apart. Most women find morning and evening application convenient.
• Do not wash the treated areas for at least 4 hours after application.
• Wait at least 5 minutes after application before applying sunscreen, moisturiser, or cosmetics.
• If you have just removed facial hair (by shaving, threading, plucking, or waxing), wait at least 5 minutes before applying Vaniqa to avoid stinging.
• Avoid contact with the eyes, nostrils, mouth, and any broken or irritated skin.
• Wash your hands after application.

Side effects of Vaniqa

Common side effects

The most frequently reported side effects are localised skin reactions at the application site.

Acne and acneiform eruptions are the most common, occurring in approximately 7 to 14% of users. This may be partly attributed to the cream base occluding follicular openings.

Skin burning, stinging, or tingling is reported by 1 to 4% of users and is usually mild and self-limiting. Skin dryness, redness, and itching may also occur.

Folliculitis (inflamed or infected hair follicles) and ingrown hairs are common, particularly in women who shave or wax the treated areas.

Uncommon and rare side effects

Uncommonly reported effects include contact dermatitis, papular rash, localised alopecia (hair thinning in the treated area), and numbness or paraesthesia.

Bleeding skin from excessive scratching or irritation has been reported rarely. Systemic side effects are extremely rare due to the very low percutaneous absorption of eflornithine.

However, application to broken or severely irritated skin may increase absorption and local reactions.

When to seek medical advice

Mild stinging or redness after application is normal and usually settles within minutes.

Contact your GP, pharmacist, or NHS 111 if local irritation is persistent, worsening, or accompanied by blistering, crusting, or oozing.

Seek emergency medical help by calling 999 or attending A&E if you develop signs of a serious allergic reaction, including widespread rash, swelling of the face, lips, or tongue, or difficulty breathing.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Underlying cause of hirsutism

Before starting Vaniqa, the underlying cause of facial hirsutism should be investigated.

Your GP may arrange blood tests including serum testosterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulphate (DHEAS), 17-hydroxyprogesterone, thyroid function, and prolactin.

A pelvic ultrasound may be requested if PCOS is suspected.

Identifying and treating the underlying hormonal cause (for example, with combined oral contraceptives or anti-androgens such as spironolactone in PCOS) may complement the topical effects of Vaniqa and provide more comprehensive management.

Pregnancy and breastfeeding

The safety of Vaniqa during pregnancy has not been established in adequate human studies.

Animal reproductive toxicity studies showed adverse effects at systemic exposures far exceeding those achieved with topical use, but in the absence of human data, a precautionary approach is advised.

Women who are pregnant or planning a pregnancy should not use Vaniqa unless the expected benefit outweighs the potential risk, after discussion with their prescriber.

It is not known whether eflornithine is excreted in human breast milk, and a decision should be made whether to discontinue breastfeeding or to discontinue treatment.

Skin conditions

Patients with pre-existing skin conditions such as rosacea, eczema (atopic dermatitis), or acne may be more susceptible to local irritation from Vaniqa.

A small test application to a limited area may be advisable before commencing full treatment.

If irritation persists or worsens despite continued use, treatment should be stopped and the prescriber consulted.

How to get a Vaniqa prescription in the UK

Vaniqa is classified as a prescription-only medicine (POM) in the UK.

It can be prescribed by GPs, dermatologists, gynaecologists, or endocrinologists who have investigated the cause of facial hirsutism and determined that topical treatment is appropriate.

Some integrated care boards (formerly clinical commissioning groups) have local prescribing restrictions on Vaniqa, and in some areas a specialist referral may be required before it is initiated on NHS prescription.

Your GP can advise on local availability.

Vaniqa may also be prescribed by authorised online prescribers registered with the General Pharmaceutical Council (GPhC) or the Care Quality Commission (CQC) following an appropriate clinical consultation.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Each tube of Vaniqa contains 60 g of cream, which typically lasts approximately 2 months when used as directed.

Living with facial hirsutism: practical management

Managing facial hirsutism involves a combination of medical treatment, hair removal techniques, and psychological support.

Physical hair removal options include shaving (which is safe and does not cause hair to grow back thicker), threading, waxing, epilation, depilatory creams, and laser or intense pulsed light (IPL) treatment.

Laser hair removal and IPL are most effective for women with dark hair and light skin, and usually require multiple sessions.

These treatments may be available through the NHS in some areas for women with severe hirsutism, although private treatment is more commonly used.

The psychological impact of facial hirsutism should not be underestimated.

Studies have shown that women with visible facial hair frequently report anxiety, depression, social avoidance, reduced self-esteem, and impaired quality of life.

If you are struggling with the emotional impact of facial hair growth, speak with your GP about referral to a counsellor, psychologist, or a support group such as those facilitated by Verity (the UK PCOS charity).

Addressing the psychological dimensions of hirsutism is as important as managing the physical symptoms.

When to seek medical advice

Consult your GP if you develop new or worsening facial hair growth, especially if accompanied by irregular periods, acne, weight gain, or hair thinning on the scalp, as these features may suggest an underlying hormonal condition requiring investigation.

Seek urgent medical advice if facial hair growth develops rapidly or is associated with voice deepening, muscle changes, or other signs of virilisation, as this may indicate an androgen-secreting tumour requiring specialist referral.

Report any suspected adverse reactions to Vaniqa via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Vaniqa 11.5% cream, Summary of Product Characteristics (EMC)
• Eflornithine, British National Formulary (BNF)
• Hirsutism, NICE Clinical Knowledge Summaries
• Excessive hair growth (hirsutism), NHS
• MHRA Yellow Card Scheme